SAN DIEGO, Oct. 6, 2014 (GLOBE NEWSWIRE) -- AltheaDx, Inc. ("AltheaDx" or the "Company"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced the recent appointment of Bruce Bodaken, Karin Eastham and Jorge Garces to the Company's board of directors. The appointments increase the number of directors from seven to ten.
"We are delighted to expand our Board with the inclusion of such high caliber individuals," said François Ferré, Ph.D, co-founder of AltheaDx and co-Chairman of the Company's board of directors. "We believe the addition of these members to our existing Board will provide valuable perspective as we continue to grow and focus on executing our strategy."
"The addition of Bruce, Karin and Jorge is a positive step for the Company, adding further strength and range to our Board," added Matt Mackowski, co-Chairman of the Company's board of directors.
Mr. Bodaken served as the Chairman and Chief Executive Officer of Blue Shield of California from January 2000 to December 2012, and currently serves on the boards of directors of Rite Aid Corporation and WageWorks, Inc., a consumer directed health plan provider. He also serves on the board of directors of the Institute of Medicine's Roundtable on Value and Science-Driven Healthcare, and is a visiting scholar at the Brookings Institution. Mr. Bodaken recently joined the faculty at University of California, Berkeley, in the Division of Health Policy Management. He is a co-author (with Robert Fritz) of The Managerial Moment of Truth, and taught philosophy at the university level before his career in health care. Mr. Bodaken holds an M.A. in Philosophy from the University of Colorado and a B.A. in Philosophy from Colorado State University.
Ms. Eastham serves on the boards of directors of lllumina, Inc., a biotechnology company, Veracyte, Inc. a healthcare diagnostics company, MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company, and Geron Corporation, a biotechnology company. She also served as Executive Vice President and Chief Operating Officer, and a member of the Board of Trustees of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company. Ms. Eastham holds a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.
Dr. Garces has served as the Company's President since February 2014 and as its Chief Operating Officer since June 2013. Prior to joining the Company, he served as Senior Vice President, Research and Development of GenMark Diagnostics, Chief Executive Officer and President of Enigma Diagnostics, Inc., and Vice President and Site Operations Manager of Hologic, Inc. (formerly Third Wave Technologies Inc.), where he led the development and submission to the FDA for approval of their cystic fibrosis and human papillomavirus products. Dr. Garces also held senior roles at clinical diagnostic laboratories including Genzyme Genetics and Athena Diagnostics, Inc. Dr. Garces earned his Ph.D. in Cell and Molecular Biology from the City University of New York. He completed his post-doctoral training at the University of Massachusetts Medical School and received an M.B.A. from the Kellogg Graduate School of Management. Dr. Garces received a Bachelor's degree in Biology from the City University of New York, Brooklyn College.
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
CONTACT: Kristen Nungesser ICR, Inc. (646) 277-1261 email@example.comSource:AltheaDx, Inc.